Novo Nordisk's China Filing Sets Up a London Showdown Investors Are Watching Closely

Novo Nordisk's oral Wegovy application accepted in China, offering a growth angle ahead of its September capital markets day, despite analyst skepticism.

The Danish drugmaker's submission to Chinese regulators has handed Novo Nordisk a fresh growth narrative just as skepticism about its pipeline deepens. Whether that story survives contact with the capital markets day in September is now the central question for shareholders.

The China Gambit

China's National Medical Products Administration has accepted Novo Nordisk's marketing application for the oral version of Wegovy, the company confirmed on August 27. The move does not constitute approval — it simply opens the formal review process for the weight-loss treatment in the world's second-largest pharmaceuticals market.

The distinction matters more than it might appear. Chinese regulatory reviews can stretch through multiple rounds of questioning, and the NMPA retains the right to demand supplementary clinical data at any stage. For investors, the filing acceptance is a procedural milestone, not a commercial breakthrough.

Still, the strategic logic is clear. An oral formulation could resonate with a Chinese patient population that has historically shown reluctance toward injectable therapies. With Eli Lilly intensifying competition across global markets, Novo Nordisk needs every geographic advantage it can secure — and China represents one of the largest untapped patient pools for obesity treatments anywhere.

A Pipeline Story With Two Sides

The China news arrived during a stretch that has tested investor patience on multiple fronts. Deutsche Bank downgraded the stock from Hold to Sell on August 27, trimming its price target to 265 Danish kroner from 290. The bank cited softening growth expectations for 2027, pipeline setbacks — including the late-stage failure of the cardiovascular candidate Ziltivekimab — and the looming threat of patent expiries. Berenberg had already pulled its rating back from Buy to Hold on August 17.

Yet the company has continued to advance its research agenda on other tracks. Novo Nordisk is now testing lower doses of its oral Wegovy tablet and has added an early-stage obesity candidate to its development roster. The company is also investigating whether semaglutide, the active ingredient behind both Wegovy and Ozempic, could be repurposed for Alzheimer's disease — a sign that management intends to stretch its GLP-1 franchise well beyond metabolic disorders.

External partnerships are contributing as well. Lexicon Pharmaceuticals received a third milestone payment of $10 million in late August tied to the jointly developed candidate LX9851, an arrangement that spreads development risk while expanding Novo Nordisk's research base.

The Numbers Tell a Cautious Tale

The market's mixed reception to these developments shows up in the stock's technical position. The shares trade at roughly €40.58, about one percent above their 200-day average of €40.17 — evidence that the medium-term floor may be stabilizing. But the picture is less reassuring on a shorter horizon: the stock sits roughly 2.1 percent below its 50-day average of €41.68, suggesting the recent recovery has yet to establish a clear upward trend.

Annualized volatility of 41 percent underscores how far the stock has drifted from the placid profile investors once expected from an established pharmaceutical heavyweight. That figure reflects genuine two-sided uncertainty — about the NMPA's timeline, about Eli Lilly's competitive trajectory, and about whether Novo Nordisk can defend its growth rates as patent cliffs approach.

What September Will Reveal

The immediate test arrives on September 21, when Novo Nordisk hosts its capital markets day in London. Management is expected to lay out its growth strategy beyond 2026, and the China filing gives them a concrete data point to cite. Whether that translates into a coherent expansion narrative — or gets drowned out by questions about Lilly and the pipeline — will depend on the detail executives provide.

The company continues to work through a 15 billion kroner share buyback program, a capital return plan that signals confidence in the company's own valuation even as external analysts grow more cautious.

Third-quarter results follow on November 4, offering the next hard look at whether commercial momentum can offset the structural concerns. Until then, the China application remains what it is: an accepted filing, a foot in the door, and a reason for the bulls to keep talking — but not yet proof that Novo Nordisk has solved the growth problem that has analysts hedging their bets.